PCRX VS WRBY Stock Comparison
Performance
PCRX10/100
10/100
PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
WRBY10/100
10/100
WRBY returned -37.86% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
PCRX67/100
67/100
16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.
WRBY
"Analyst Price Targets" not found for WRBY
Technicals
PCRX21/100
21/100
PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
WRBY25/100
25/100
WRBY receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
Earnings
PCRX10/100
10/100
PCRX has missed earnings 8 times in the last 20 quarters.
WRBY10/100
10/100
WRBY has missed earnings 4 times in the last 20 quarters.
Profit
PCRX55/100
55/100
Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.
WRBY10/100
10/100
Out of the last 13 quarters, WRBY has had 1 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
PCRX45/100
45/100
PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
WRBY50/100
50/100
WRBY has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Pacira BioSciences, Inc. Common Stock Summary
Nasdaq / PCRX
Healthcare
Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Warby Parker Inc. Summary
New York Stock Exchange / WRBY
Healthcare
Medical - Instruments & Supplies
Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores, website, and mobile apps. As of May 16, 2022, it had 160 retail stores in the United States and Canada. The company was formerly known as JAND, Inc. and changed its name to Warby Parker Inc. in June 2021. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PCRX to other companies in the same or a similar industry.
